BMP-3 products

• US 6,177,406 B1
• Filed: 09/05/1997
• Issued: 01/23/2001
• Est. Priority Date: 07/01/1986
• Status: Expired due to Fees

• Current Assignee: Genetics Institute LLC (Pfizer Inc.)
• Original Assignee: Genetics Institute LLC (Pfizer Inc.)
• Inventors: Wozney, John M., Rosen, Vicki, Wang, Elizabeth A.
• Primary Examiner(s): Romeo, David S.
• Application Number:
  US08/927,124
• Time in Patent Office: 1,236 Days
• Field of Search: 530/350, 530/324, 530/399, 514/12
• US Class Current: 424/484
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61L 24/043 Mixtures of macromolecular materials
• CPC Class Codes: A61L 27/227 Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: C08L 89/00 Compositions of proteins; Compositions of derivatives thereof foodstuff preparations A23J3/00

Abstract

Purified BMP-3 proteins and processes for producing them are disclosed. They may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

Claims

1. An isolated bone morphogenetic protein -3 (BMP-3) comprising an amino acid sequence selected from the group consisting of:

(a) amino acids 1 through 175 of FIGS. 1A-1B; and

(b) amino acids 377 through 472 of FIGS. 2A-2C.

2. The protein of claim 1 further characterized by the ability to induce the formation of cartilage and/or bone.

3. A pharmaceutical composition comprising a BMP-3 of claim 1 in admixture with a pharmaceutically acceptable vehicle.

4. A composition for bone and/or cartilage formation comprising an amount effective for the induction of bone and/or cartilage formation in a patient in need of same of BMP-3 of claim 1 in a pharmaceutically acceptable vehicle.

5. The composition of claim 4 further comprising a matrix for supporting said composition and providing a surface for bone and/or cartilage growth.

6. The composition of claim 5 wherein said matrix comprises a material selected from the group consisting of hydroxyapatite, collagen, polylactic acid and tricalcium phosphate.

7. A method for inducing formation of chondrocyte and/or cartilage tissue in a patient comprising minister to said patient a composition comprising an amount of the BMP-3 of claim 1 effective to induce formation of chondrocyte and/or cartilage tissue.

8. A purified BMP-3 polypeptide comprising the amino acid sequence set forth in FIGS. 2A-2C encoded by nucleotides 321 through 1736 of FIGS. 2A-2C.

9. An isolated bone morphogenetic protein comprising two subunits wherein comprise said subunits comprises an amino acid sequence selected from the group consisting of:

(a) amino aids 1 through 175 of FIGS. 1A-1B; and

(b) amino acids 377 through 472 of FIGS. 2A-2C.